Hagens Berman says investors who bought shares during the May 13, 2025-Feb. 19, 2026 class period can seek lead-plaintiff status after the company missed its primary trial endpoint and lost more than $2.2 billion in value.
A securities fraud class action has been filed against GRAIL, Inc. (NASDAQ: GRAL) over statements tied to its NHS-Galleri cancer-screening trial, and Hagens Berman Sobol Shapiro LLP said investors who bought shares from May 13, 2025, to Feb. 19, 2026 have until Aug. 4, 2026 to seek appointment as lead plaintiff. The complaint alleges GRAIL and certain senior executives portrayed the trial's design, progress and efficacy as sufficient to show a statistically significant reduction in late-stage Stage III and IV cancers after three years, while selectively highlighting favorable early screening results and withholding detailed data that suggested the timeline was too short to reach the primary endpoint. The case points to Feb. 19, 2026 disclosures in which GRAIL said the study did not meet that endpoint and admitted it "probably should have allowed for a longer follow-up period," sending the stock down 50.55% to $50.21 from $101.53 on Feb. 20 and wiping out more than $2.2 billion in market capitalization. Hagens Berman said it is also examining when GRAIL and management first recognized the follow-up period issue, while urging whistleblowers with non-public information to consider the SEC Whistleblower program.